Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide

Restricted access

Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer. The clinical impact of MCC has been increasing due to steadily rising incidence rates. Since 2001, more than 24,000 cases of MCC have been reported to the US National Program of Cancer Registries database, and in 2018, more than 2,500 incident cases are expected. MCC is highly aggressive, and one-third of patients will either present with or develop metastatic disease. Outcomes in patients with metastatic MCC have historically been poor; median time to progression with cytotoxic chemotherapy is only 3 months. MCC has long been appreciated to be immunogenic, with reports of spontaneous regression and responsiveness to immunotherapy. However, the mechanisms of this immunogenicity have only been understood over the past decade, with approximately 80% of cases in the United States associated with the Merkel cell polyomavirus (MCPyV) and expression of viral antigens (virus-positive [VP] MCC), and the remaining 20% of cases caused by UV radiation–induced damage leading to a high mutational burden and expression of neoantigens (virus-negative [VN] MCC). These insights have led to multiple successful trials of immunotherapies for MCC. PD-1 axis checkpoint inhibitors are now regarded as the preferred frontline systemic therapy in eligible patients (including both VP- and VN-MCC), with impressive frequency, durability, and depth of objective responses, which compare favorably to those of most solid tumors. This article reviews the safety and efficacy data from the key clinical trials of immune checkpoint inhibitors for metastatic MCC, and discusses several issues relevant to the clinical use of these agents. Finally, emerging immunotherapies for MCC, including cellular therapies and adjuvant systemic therapies, are reviewed.

Correspondence: Shailender Bhatia, MD, Division of Medical Oncology, Department of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Mailstop #CE2-102, Seattle, WA 98109. Email: sbhatia@uw.edu
  • 1.

    HeathMJaimesNLemosB. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol2008;58:375381.

    • Search Google Scholar
    • Export Citation
  • 2.

    EngelsEAFrischMGoedertJJ. Merkel cell carcinoma and HIV infection. Lancet2002;359:497498.

  • 3.

    IyerJGAfanasievOKMcClurkanC. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res2011;17:66716680.

    • Search Google Scholar
    • Export Citation
  • 4.

    2001–2014 Database: National Program of Cancer Registries and Surveillance Epidemiology and End Results SEER*Stat Database: NPCR and SEER Incidence – USCS 2001–2014 Public Use Research DatabaseUnited States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released August 2017 based on the November 2016 submission. Available at: www.cdc.gov/cancer/npcr/public-use. Accessed June 15 2018.

    • Search Google Scholar
    • Export Citation
  • 5.

    PaulsonKGParkSYVandevenNA. Merkel cell carcinoma: current United States incidence and projected increases based on changing demographics. J Am Acad Dermatol2018;78:457463.

    • Search Google Scholar
    • Export Citation
  • 6.

    KimJAChoiAH. Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: a propensity score Surveillance, Epidemiology, and End Results database analysis. JAMA Dermatol2013;149:831838.

    • Search Google Scholar
    • Export Citation
  • 7.

    BichakjianCKOlenckiTAasiSZ. NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma Version 1.2018. Accessed May 24 2018. To view the most recent version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 8.

    SivaSByrneKSeelM. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med2013;54:12231229.

    • Search Google Scholar
    • Export Citation
  • 9.

    FieldsRCBusamKJChouJF. Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg2011;254:465475.

  • 10.

    KouzminaMKoljonenVLeikolaJ. Frequency and locations of systemic metastases in Merkel cell carcinoma by imaging. Acta Radiol Open2017;6:2058460117700449.

    • Search Google Scholar
    • Export Citation
  • 11.

    AsgariMMSokilMMWartonEM. Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol2014;150:716723.

    • Search Google Scholar
    • Export Citation
  • 12.

    NghiemPKaufmanHLBharmalM. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol2017;13:12631279.

    • Search Google Scholar
    • Export Citation
  • 13.

    BeckerJCLorenzEUgurelS. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget2017;8:7973179741.

    • Search Google Scholar
    • Export Citation
  • 14.

    FengHShudaMChangYMoorePS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science2008;319:10961100.

  • 15.

    PastranaDVTolstovYLBeckerJC. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog2009;5:e1000578.

  • 16.

    CarterJJPaulsonKGWipfGC. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst2009;101:15101522.

    • Search Google Scholar
    • Export Citation
  • 17.

    ChenTHedmanLMattilaPS. Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol2011;50:125129.

    • Search Google Scholar
    • Export Citation
  • 18.

    ShudaMFengHKwunHJ. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A2008;105:1627216277.

    • Search Google Scholar
    • Export Citation
  • 19.

    BeckerJCStangADeCaprioJA. Merkel cell carcinoma. Nat Rev Dis Primers2017;3:17077.

  • 20.

    KwunHJShudaMFengH. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe2013;14:125135.

    • Search Google Scholar
    • Export Citation
  • 21.

    ShudaMChangYMoorePS. Merkel cell polyomavirus-positive Merkel cell carcinoma requires viral small T-antigen for cell proliferation. J Invest Dermatol2014;134:14791481.

    • Search Google Scholar
    • Export Citation
  • 22.

    ShudaMKwunHJFengH. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest2011;121:36233634.

    • Search Google Scholar
    • Export Citation
  • 23.

    LyngaaRPedersenNWSchramaD. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res2014;20:17681778.

    • Search Google Scholar
    • Export Citation
  • 24.

    PaulsonKGIyerJGTegederAR. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol2011;29:15391546.

    • Search Google Scholar
    • Export Citation
  • 25.

    MillerNJChurchCDDongL. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol Res2017;5:137147.

    • Search Google Scholar
    • Export Citation
  • 26.

    PaulsonKGLewisCWRedmanMW. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study. Cancer2017;123:14641474.

    • Search Google Scholar
    • Export Citation
  • 27.

    GarneskiKMWarcolaAHFengQ. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol2009;129:246248.

    • Search Google Scholar
    • Export Citation
  • 28.

    MoshiriASDoumaniRYelistratovaL. Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol2017;137:819827.

    • Search Google Scholar
    • Export Citation
  • 29.

    NghiemPTBhatiaSLipsonEJ. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med2016;374:25422552.

  • 30.

    GohGWalradtTMarkarovV. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget2016;7:34033415.

    • Search Google Scholar
    • Export Citation
  • 31.

    PaulsonKGLemosBDFengB. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol2009;129:15471555.

    • Search Google Scholar
    • Export Citation
  • 32.

    HarmsPWCollieAMHovelsonDH. Next generation sequencing of cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol2016;29:240248.

    • Search Google Scholar
    • Export Citation
  • 33.

    HarmsPWVatsPVerhaegenME. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res2015;75:37203727.

    • Search Google Scholar
    • Export Citation
  • 34.

    YarchoanMHopkinsAJaffeeEM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med2017;377:25002501.

  • 35.

    PaulsonKGIyerJGBlomA. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol2013;133:642646.

    • Search Google Scholar
    • Export Citation
  • 36.

    DowlatshahiMHuangVGehadAE. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol2013;133:18791889.

    • Search Google Scholar
    • Export Citation
  • 37.

    AfanasievOKYelistratovaLMillerN. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res2013;19:53515360.

    • Search Google Scholar
    • Export Citation
  • 38.

    BhatiaSIyerJIbraniD. Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: final results of a phase 2 study [abstract]. Eur J Cancer2015;51(Suppl 3):Abstract 504.

    • Search Google Scholar
    • Export Citation
  • 39.

    BhatiaSMillerNLuHL. Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): final clinical results and immunologic effects on the tumor microenvironment (TME) [abstract]. J Clin Oncol2016;34(Suppl 15):Abstract 3021.

    • Search Google Scholar
    • Export Citation
  • 40.

    ChapuisAGAfanasievOKIyerJG. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res2014;2:2736.

    • Search Google Scholar
    • Export Citation
  • 41.

    PaulsonKGPerdicchioMKulikauskasR. Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab [abstract]. J Clin Oncol2017;35(Suppl 15):Abstract 3044.

    • Search Google Scholar
    • Export Citation
  • 42.

    KaufmanHLRussellJHamidO. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol2016;17:13741385.

    • Search Google Scholar
    • Export Citation
  • 43.

    KaufmanHRussellJHamidO. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer2018;6:7.

    • Search Google Scholar
    • Export Citation
  • 44.

    CoweyCLMahnkeLEspiritoJ. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol2017;13:16991710.

    • Search Google Scholar
    • Export Citation
  • 45.

    D'AngeloSPRussellJHasselJC. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): preliminary data from an ongoing study [abstract]. J Clin Oncol2017;35(Suppl 15):Abstract 9530.

    • Search Google Scholar
    • Export Citation
  • 46.

    TopalianSLBhatiaSHollebecqueA. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC) [abstract]. Cancer Res2017;77(Suppl 13):Abstract CT074.

    • Search Google Scholar
    • Export Citation
  • 47.

    KaufmanHLHungerMHennessyM. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncol2018;14:255266.

    • Search Google Scholar
    • Export Citation
  • 48.

    HarrisJSengarDStewartTHyslopD. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer1976;37:10581069.

    • Search Google Scholar
    • Export Citation
  • 49.

    HaanenJCarbonnelFRobertC. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2017;28:iv119142.

    • Search Google Scholar
    • Export Citation
  • 50.

    PuzanovIDiabAAbdallahK. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer2017;5:95.

    • Search Google Scholar
    • Export Citation
  • 51.

    KittaiASOldhamHCetnarJTaylorM. Immune checkpoint inhibitors in organ transplant patients. J Immunother2017;40:277281.

  • 52.

    Abdel-WahabNShahMLopez-OlivoMASuarez-AlmazorME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med2018;168:121130.

    • Search Google Scholar
    • Export Citation
  • 53.

    JessurunCAVosJALimpensJLuitenRM. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Front Oncol2017;7:233.

    • Search Google Scholar
    • Export Citation
  • 54.

    WinklerJKDimitrakopoulou-StraussASachpekidisC. Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. J Eur Acad Dermatol Venereol2017;31:e389391.

    • Search Google Scholar
    • Export Citation
  • 55.

    KimJMChenDS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol2016;27:14921504.

  • 56.

    MartiniDJLalaniAABosseD. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer2017;5:66.

    • Search Google Scholar
    • Export Citation
  • 57.

    ItoYKawamuraKMiuraT. Merkel cell carcinoma. A successful treatment with tumor necrosis factor. Arch Dermatol1989;125:10931095.

  • 58.

    HataYMatsukaKItoO. Two cases of Merkel cell carcinoma cured by intratumor injection of natural human tumor necrosis factor. Plast Reconstr Surg1997;99:547553.

    • Search Google Scholar
    • Export Citation
  • 59.

    PaulsonKGTegederAWillmesC. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res2014;2:10711079.

    • Search Google Scholar
    • Export Citation
  • 60.

    DurandJMWeillerCRichardMA. Treatment of Merkel cell tumor with interferon-alpha-2b. Br J Dermatol1991;124:509.

  • 61.

    Biver-DalleCNguyenTTouzeA. Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol2011;50:479480.

    • Search Google Scholar
    • Export Citation
  • 62.

    WahlRUBraunschweigTGhassemiARubbenA. Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma. Curr Oncol2016;23:e150153.

    • Search Google Scholar
    • Export Citation
  • 63.

    BlackmonJTDhawanRViatorTM. Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: a report of 2 cases. JAAD Case Rep2017;3:185189.

    • Search Google Scholar
    • Export Citation
  • 64.

    KwilasARDonahueRNBernsteinMBHodgeJW. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol2012;2:104.

    • Search Google Scholar
    • Export Citation
  • 65.

    IyerJGParvathaneniUGooleyT. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med2015;4:11611170.

    • Search Google Scholar
    • Export Citation
  • 66.

    CotterSEDunnGPCollinsKM. Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol2011;147:870872.

    • Search Google Scholar
    • Export Citation
  • 67.

    NathanPDGauntPWheatleyK. UKMCC-01: a phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma [abstract]. J Clin Oncol2016;34(Suppl 15):Abstract 9542.

    • Search Google Scholar
    • Export Citation
  • 68.

    FakihaMLetertrePVuillezJPLebeauJ. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther2010;6:382384.

    • Search Google Scholar
    • Export Citation
  • 69.

    SlotkinEKPatwardhanPPVasudevaSD. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther2015;14:395406.

    • Search Google Scholar
    • Export Citation
  • 70.

    SnyderAMakarovVMerghoubT. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med2014;371:21892199.

  • 71.

    JouaryTLeyralCDrenoB. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol2012;23:10741080.

    • Search Google Scholar
    • Export Citation
  • 72.

    RushZFieldsRCLeeNBrownellI. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol2011;6:395404.

    • Search Google Scholar
    • Export Citation
  • 73.

    BhatiaSStorerBEIyerJG. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst2016;108:djw042.

    • Search Google Scholar
    • Export Citation
  • 74.

    MojicaPSmithDEllenhornJD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol2007;25:10431047.

    • Search Google Scholar
    • Export Citation
  • 75.

    GarneskiKMNghiemP. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol2007;57:166169.

    • Search Google Scholar
    • Export Citation
  • 76.

    PoulsenMRischinDWalpoleE. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study—TROG 96:07. J Clin Oncol2003;21:43714376.

    • Search Google Scholar
    • Export Citation
  • 77.

    FrohmMLGriffithKAHarmsKL. Recurrence and survival in patients with Merkel cell carcinoma undergoing surgery without adjuvant radiation therapy to the primary site. JAMA Dermatol2016;152:10011007.

    • Search Google Scholar
    • Export Citation
  • 78.

    PaulsonKGVoilletVPerdicchioM. Acquired Cancer Resistance to Combination Immunotherapy from Transcriptional Loss of Class I HLA. Submitted.

    • Search Google Scholar
    • Export Citation
  • 79.

    PaulsonKGCarterJJJohnsonLG. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res2010;70:83888397.

    • Search Google Scholar
    • Export Citation
  • 80.

    SamimiMMoletLFleuryM. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol2016;174:813822.

    • Search Google Scholar
    • Export Citation
  • 81.

    GunaratneDAHowleJRVenessMJ. Definitive radiotherapy for Merkel cell carcinoma confers clinically meaningful in-field locoregional control: a review and analysis of the literature. J Am Acad Dermatol2017;77:142148e1.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 336 336 18
PDF Downloads 136 136 11
EPUB Downloads 0 0 0